Bristol-Myers Squibb Compnay

Pfizer Corporation

Pfizer Products Inc.

Louis Stanley Chupak

Xiaofan Zheng

Min Ding

Robert G Gentles

Scott W Martin

Yazhong Huang

Richard Eric Olson

Upender Velaparthi

Allen Jacob Duplantier

Anthony John Milici

Piyasena Hewawasam

Kap-Sun Yeung

Jayakumar Sankara Warrier

Mark Carl Noe

Prasada Rao Jalagam

Saumya Roy

John F Kadow

Michael Anthony Letavic

John A Bender

John S Tokarski

Ivar M McDonald

Katharine A Grant-Young

Kyle E Parcella

Ying Han

Bireshwar Dasgupta

Brett R Beno

Kim F McClure

Chetan Padmakar Darne

Hasibur Rahaman

Andrew Nickel

Gopikishan Tonukunuru

Raju Mannoori

Richard Pracitto

Wan F Lau

Manjunatha Narayana Rao Kamble

Sivasudar Velaiah

Kotha Rathnakar Reddy

Thiruvenkadam Raja

Shuanghua Hu

Paul Michael Scola

Takushi Kaneko

David R Langley

Mark Edward Flanagan

Xiaojun Zhang

Timothy P Connolly

Thomas V Magee

Stephen E Mercer

Usa Reilly

Ningning Xu

Juliang Zhu

Ivar M Mcdonald

Daniel J Tenney

Denise Christine Grunenfelder

Michael Wichroski

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; Y is CRor N; R, R, R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted bicyclic compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Naphthyridinone compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK&#x3b1;) and diacylglycerol kinase zeta (DGK&#x3b6;), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted naphthyridinone compounds useful as T cell activators

Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one Ris H and the other Ris an aryl group substituted with zero to 3 R; and R, R, and Rare defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors for the inhibition or prevention of platelet aggregation, and the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. Also disclosed are methods of using such compounds for the treatment of human papillomavirus. Additionally, pharmaceutical compositions comprising at least one compound of Formula (I) are disclosed. 

Aryl substituted bicycle heteroaryl compounds

Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of virological diseases or disorders and cancer. 

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Compounds for the treatment of hepatitis C

The present disclosure is generally directed to compounds that can inhibit DAGL&#x3b1; and/or &#x3b2; activity, compositions comprising such compounds, and methods for inhibiting DAGL&#x3b1; and/or &#x3b2; activity.

Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase

Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

Macrolides

This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate ICs of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins). This invention also relates to compounds, methods of treatment and composition of Formula I:or a therapeutically acceptable salt thereof, wherein

Selective inhibition of aggrecanase in osteoarthritis treatment

Growing community of inventors

Old Saybrook, CT, United States of America

Louis Stanley Chupak